(:OYST)

Dec 21, 2022 10:20 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, ELVT, LBC, OYST
NEW YORK, Dec. 21, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 20, 2022 11:52 am ET
INVESTOR ALERT: The M&A Class Action Firm Launches Legal Inquiry Regarding the Merger – IMGO, OYST, RBA, BNFT
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Dec 15, 2022 07:04 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, SAL, LBC, OYST
NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 14, 2022 04:00 pm ET
EQUITY ALERT: Contact the M&A Class Action Firm Regarding Its Investigation of the Merger – ELVT, OYST, LBC, RBA
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Dec 07, 2022 11:31 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGFS, ATCO, LBC, OYST
NEW YORK, Dec. 8, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 07, 2022 04:54 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Reminds Investors of Its Ongoing Inquiry Regarding the Merger – OYST, PFHD, SMBC, LBC
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Dec 07, 2022 11:24 am ET
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oyster Point Pharma, Inc. (NasdaqGS: OYST) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Oyster Point will receive $11.00 in cash plus a contingent value right for a potential cash payment of up to $2.00 per share, for each share of Oyster Point that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration underva
Dec 02, 2022 08:00 am ET
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Dec 01, 2022 02:28 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, BNFT, IMGO, OYST
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Lakeland Bancorp, Inc. (NASDAQ:...
Nov 30, 2022 07:46 pm ET
Lifshitz Law PLLC Announces Investigations of ELVT, OPNT, WAFD, and OYST
Elevate Credit, Inc. (NYSE: ELVT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of ELVT to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are an...
Nov 29, 2022 10:34 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OYST, LBC, ELVT, IMGO
NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 28, 2022 04:00 pm ET
SHAREHOLDER ALERT: Contact the M&A Class Action Firm to Inquire about its Investigation of the Merger – SBCF, OYST, RCOR, SMBC
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Nov 23, 2022 09:27 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, USER, AGFS, OYST
NEW YORK, Nov. 23, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 20, 2022 10:51 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCO, IAA, OYST
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Corp. (NYSE: ATCO)’s sale to...
Nov 19, 2022 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of RBA, OYST, LMST, and IAA
Ritchie Bros. Auctioneers Incorporated (NYSE: RBA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IAA, Inc. to RBA for $10.00 per share in cash and 0.5804 shares of RBA common...
Nov 15, 2022 09:45 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ABMD, BNFT, OYST, VLDR
NEW YORK, Nov. 15, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 14, 2022 09:45 pm ET
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Oyster Point Pharma, Inc. - OYST
NEW YORK, Nov. 14, 2022 /PRNewswire/-- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Oyster Point Pharma, Inc. (OYST), relating to its proposed acquisition by Viatris Inc. Under the terms of the agreement, OYST shareholders will receive $11.00 in cash plus up to $2.00 per share in CVRs per share they own. Click here for mo
Nov 13, 2022 01:51 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IAA, OYST, OUST, VLDR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: IAA, Inc. (NYSE: IAA)’s sale to...
Nov 10, 2022 04:05 pm ET
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Nov 08, 2022 07:09 pm ET
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oyster Point Pharma, Inc. (NasdaqGS: OYST) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Oyster Point will receive $11.00 in cash plus a contingent value right for a potential cash payment of up to $2.00 per share, for each share of Oyster Point that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration underva
Nov 08, 2022 01:39 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OYST, OUST, AGTC
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Oyster Point Pharma, Inc. (NASDAQ:...
Nov 08, 2022 12:17 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD),
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Nov 07, 2022 09:46 pm ET
Nov 07, 2022 04:39 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLC Investigates OYST, OUST, and RBA
NEW YORK, Nov. 7, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders:
Nov 07, 2022 11:04 am ET
OYST Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Oyster Point Pharma, Inc.
The law firm of Wohl & Fruchter LLP is investigating whether the directors of Oyster Point Pharma, Inc. (Nasdaq: OYST) (“Oyster”) acted in the best interests of Oyster shareholders in approving the sale of Oyster to Viatris Inc. (“Viatris”) for...
Nov 07, 2022 10:15 am ET
Shareholder Alert: Ademi LLP investigates whether Oyster Point Pharma, Inc. has obtained a Fair Price in its transaction with Viatris
MILWAUKEE, Nov. 7, 2022 /PRNewswire/ -- Ademi LLP is investigating Oyster Point Pharma (NASDAQ: OYST) for possible breaches of fiduciary duty and other violations of law in its transaction with Viatris. 
Nov 07, 2022 09:06 am ET
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Oyster Point Pharma, Inc. (NASDAQ: OYST) to Viatris Inc. for $11.00 per share in cash plus a contingent value right for a potential cash payment of up to $2.00 per share is fair to Oyster Point shareholders.
Nov 07, 2022 08:00 am ET
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), today announced that it has entered into a definitive agreement under which Viatris Inc. (Nasdaq: VTRS), a global healthcare company, would acquire Oyster Point Pharma, a...
Nov 02, 2022 04:02 pm ET
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will...
Nov 02, 2022 08:00 am ET
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Oct 04, 2022 08:00 am ET
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Sep 27, 2022 08:00 am ET
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Sep 07, 2022 05:36 pm ET
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Aug 25, 2022 08:00 am ET
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the...
Aug 17, 2022 08:00 am ET
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Aug 15, 2022 08:00 am ET
Oyster Point Pharma To Attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Aug 11, 2022 04:01 pm ET
Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Aug 08, 2022 04:03 pm ET
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will...
Jul 27, 2022 07:00 am ET
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Jun 28, 2022 04:05 pm ET
Oyster Point Pharma Announces Operating Expense Streamlining Plan
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced it will...
Jun 15, 2022 07:55 am ET
Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that a...
May 05, 2022 04:01 pm ET
Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
May 03, 2022 04:01 pm ET
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will...
Apr 27, 2022 08:00 am ET
Oyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the...
Apr 19, 2022 08:00 am ET
Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the...
Mar 17, 2022 08:00 am ET
Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that William...
Mar 01, 2022 04:05 pm ET
Oyster Point Pharma to Participate in the Cowen 42nd Annual Health Care Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the...
Feb 24, 2022 04:01 pm ET
Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Feb 22, 2022 07:00 am ET
Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express Scripts
Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Feb 16, 2022 04:05 pm ET
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will...
Jan 04, 2022 05:08 pm ET
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oyster Point Pharma, Inc., (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the...
Dec 21, 2021 04:05 pm ET
Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the...
Dec 15, 2021 09:26 am ET
Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that Oyster...
Nov 30, 2021 07:09 pm ET
Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the...
Nov 24, 2021 07:00 am ET
Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the...
Nov 15, 2021 07:00 am ET
Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray
Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Nov 09, 2021 07:01 am ET
Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced multiple...
Nov 04, 2021 04:05 pm ET
Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat...
Nov 04, 2021 08:00 am ET
Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry
Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced it has launched a patient support program called TEAMTyrvaya™ where eligible1 patients can pay as little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg. The U.S. Food and Drug...
Nov 03, 2021 04:05 pm ET
Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Di
Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg is now available at U.S. regional wholesalers for distribution to pharmacies. The U.S. Food and Drug Administration (FDA), approved...
Nov 02, 2021 04:45 pm ET
Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced multiple...
Oct 28, 2021 07:00 am ET
Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
Oct 20, 2021 09:31 am ET
Thinking about buying stock in Oyster Point Pharma, Tegna, Compania de Minas Buenaventura, F-Star Therapeutics, or Cinedigm?
NEW YORK, Oct. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OYST, TGNA, BVN, FSTX, and CIDM.
Oct 18, 2021 08:30 am ET
Thinking about buying stock in Ion Geophysical, Valneva SE, Adamis Pharmaceuticals, Oyster Point Pharma, or InMed Pharmaceuticals?
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, VALN, ADMP, OYST, and INM.
Oct 18, 2021 06:00 am ET
Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
PRINCETON, N.J., Oct. 18, 2021 /PRNewswire/ -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that the U.S. Food and Drug Administration (FDA) has approved TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray is the first and only nasal spray approved for the treatment of dry eye disease. TYRVAYA Nasal Spray is believed to bind to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. O
Sep 01, 2021 05:24 pm ET
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the...
Aug 05, 2021 04:02 pm ET
Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma” or “the Company”) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic...
Aug 05, 2021 04:01 pm ET
Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced an exclusive...
Aug 04, 2021 08:30 am ET
Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
Aug 02, 2021 04:10 pm ET
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the...
Aug 02, 2021 04:01 pm ET
Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the...
Jul 01, 2021 06:00 am ET
Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants
Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced preclinical data in non-human primates and in vitro models evaluating OC-01 (varenicline) nasal spray against SARS-CoV-2 and the alpha and beta variants, the viruses that cause COVID-19...
Jun 29, 2021 04:42 pm ET
Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray
Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray following the announcement that an unrelated manufacturer of varenicline oral tablets has suspended...
Jun 21, 2021 04:01 pm ET
Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will...
Jun 21, 2021 07:00 am ET
Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced enrollment of the first...
Jun 10, 2021 07:00 am ET
Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced a newly formed research...
Jun 03, 2021 08:00 am ET
Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced the expansion of its...
May 06, 2021 04:01 pm ET
Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular...
May 01, 2021 08:00 am ET
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data...
Apr 30, 2021 08:00 am ET
Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
Apr 05, 2021 06:00 am ET
Oyster Point Pharma Announces New Appointment to Board of Directors
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the...
Mar 02, 2021 06:00 am ET
Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the...
Feb 25, 2021 04:01 pm ET
Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the...
Feb 18, 2021 04:01 pm ET
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular...
Feb 12, 2021 09:14 am ET
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
Dec 29, 2020 04:01 pm ET
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the...
Dec 18, 2020 07:00 am ET
Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it has...
Dec 07, 2020 07:00 am ET
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the...
Dec 01, 2020 04:01 pm ET
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it has...
Nov 25, 2020 09:00 am ET
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the...
Nov 13, 2020 07:00 am ET
Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced new data...
Nov 05, 2020 04:01 pm ET
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced its financial...
Oct 29, 2020 04:01 pm ET
Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
Oct 08, 2020 04:01 pm ET
Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced changes to...
Sep 11, 2020 08:00 am ET
Oyster Point Pharma to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the...
Aug 05, 2020 07:00 am ET
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced its financial...
Jul 31, 2020 04:01 pm ET
Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
May 19, 2020 06:08 pm ET
Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the closing of a public...
May 15, 2020 02:02 am ET
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its...
May 12, 2020 04:20 pm ET
Oyster Point Pharma Proposed Public Offering of Common Stock
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it has commenced an...
May 11, 2020 06:05 am ET
Oyster Point Pharma Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal spray versus control (p10 mm on Schirmer’s score, a...
May 11, 2020 06:00 am ET
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced its financial...
May 04, 2020 04:05 pm ET
Oyster Point Pharma to Report First Quarter 2020 Financial Results on May 11, 2020
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
Mar 30, 2020 07:30 am ET
Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and Provides COVID-19 Business Update
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced completion of...
Feb 27, 2020 04:01 pm ET
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced its financial...
Feb 24, 2020 08:00 am ET
Oyster Point Pharma to Present at the Cowen 40th Annual Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey...
Feb 24, 2020 08:00 am ET
Oyster Point Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it...
Jan 12, 2020 08:00 pm ET
Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced the positive...
Dec 23, 2019 09:00 am ET
Oyster Point Pharma Announces Addition to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the...
Dec 17, 2019 08:00 am ET
Oyster Point Pharma to Present at the 38th Annual J.P. Morgan Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey...
Dec 03, 2019 07:00 am ET
Oyster Point Pharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced its financial...
Nov 25, 2019 08:00 am ET
Oyster Point Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey...
Nov 22, 2019 05:12 pm ET
Oyster Point Pharma Announces Positive Top-Line Results From the Phase 1 “ZEN” Study of Its Lead Nicotinic Agonist Nasal Spray in Development for the Treatment of Dry Eye Disease
Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced the positive...
Nov 05, 2019 09:10 am ET
Oyster Point Pharma Announces Closing of Initial Public Offering
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced the closing of its initial...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.